培菲康在ICU危重病患者胃肠功能紊乱中的作用分析

Analysis of the role of Bifico in gastrointestinal dysfunction in critically ill patients in ICU

目的探讨双歧杆菌三联活菌(商品名:培菲康)在重症加强护理病房(ICU)危重病患者胃肠功能紊乱中的作用。方法60例ICU危重病胃肠功能紊乱患者,随机分为实验组与对照组,各30例。对照组患者采取常规肠内营养制剂治疗,实验组在对照组基础上增加培菲康治疗。比较两组治疗前后的胃肠功能评分、急性生理功能和慢性健康状况量表(APACHEⅡ)评分,Marshall评分,多器官功能障碍综合征(MODS)发生率、存活率,治疗前后胃肠道症状评分。结果治疗后,实验组胃肠功能评分(0.35±0.12)分低于对照组的(0.95±0.27)分,差异有统计学意义(P<0.05)。治疗后,实验组APACHEⅡ评分(15.68±5.12)分低于对照组的(19.32±5.27)分,差异有统计学意义(P<0.05)。治疗后,实验组Marshall评分(4.36±2.12)分低于对照组的(6.58±2.27)分,差异有统计学意义(P<0.05)。实验组MODS发生率13.33%低于对照组的40.00%,差异有统计学意义(P<0.05)。实验组存活率90.00%高于对照组的56.67%,差异有统计学意义(P<0.05)。治疗后,实验组腹胀、腹泻、便秘评分分别为(0.69±0.25)、(0.62±0.97)、(0.85±0.18)分,均低于对照组的(1.24±0.98)、(1.63±0.78)、(2.41±0.32)分,差异有统计学意义(P<0.05)。结论针对ICU危重病胃肠功能紊乱患者,通过采用培菲康加常规肠内营养制剂进行治疗,患者的腹胀、腹泻和便秘症状得到显著改善,故此种治疗方法具备比较好的临床推广意义。

Objective To discuss the role of live combined bifidobacterium,lactobacillus and enterococcus capsule(trade name:Bifico)in gastrointestinal dysfunction in critically ill patients in intensive care unit(ICU).Methods A total of 60 critically ill patients with gastrointestinal dysfunction in ICU were randomly divided into experimental group and control group,with 30 cases in each group.Patients in the control group were treated with conventional enteral nutrition preparations,and the experimental group was treated with Bifico on the basis of the control group.Both groups were compared in terms of gastrointestinal function scores,acute physiology and chronic health evaluationⅡ(APACHEⅡ)score,Marshall score,incidence of multiple organ dysfunction syndrome(MODS),survival rate,and gastrointestinal complication score before and after treatment.Results After treatment,the gastrointestinal function score(0.35±0.12)points of the experimental group was lower than(0.95±0.27)points of the control group,and the difference was statistically significant(P<0.05).After treatment,the APACHEⅡscore(15.68±5.12)points of the experimental group was lower than(19.32±5.27)points of the control group,and the difference was statistically significant(P<0.05).After treatment,the Marshall score(4.36±2.12)points of the experimental group was lower than(6.58±2.27)points of the control group,and the difference was statistically significant(P<0.05).The incidence of MODS in the experimental group was 13.33%,which was lower than 40.00%in the control group,and the difference was statistically significant(P<0.05).The survival rate of the experimental group was 90.00%,which was higher than 56.67%of the control group,and the difference was statistically significant(P<0.05).After treatment,the scores of bloating,diarrhea,and constipation in the experimental group were(0.69±0.25),(0.62±0.97),and(0.85±0.18)points,which were lower than(1.24±0.98),(1.63±0.78),and(2.41±0.32)points in the control group,and the differences were statistically significant(P<0.05).Conclusion For critically ill patients with gastrointestinal dysfunction in ICU,Bifico and conventional enteral nutrition can significantly improve the symptoms of bloating,diarrhea and constipation,so this treatment method is of great significance for clinical promotion.